1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Generics

Philippines Seeks Feedback On Plan To Recognize BE Studies Under ASEAN Deal

 
• By Vibha Sharma

The Philippines medicines regulator explains how it intends to implement the ASEAN mutual recognition agreement under which member states have committed to accept bioequivalence study reports for generics issued by approved BE centers. 

flags of ASEAN an abbreviation for the Association of Southeast Asian Nations,is a political and economic union of 10 states in Southeast Asia
The MRA Can Help Stabilize The Supply Of Generic Medicines In ASEAN Countries • Source: Shutterstock

The Philippines Food and Drug Administration is inviting stakeholder feedback on its plans to implement the Association of Southeast Asian Nations’ mutual recognition agreement (MRA) for bioequivalence (BE) study reports that aims to reduce trade barriers for generic medicines in the ASEAN region.

Key Takeaways

  • The Philippines FDA has issued a draft administrative order to officially adopt and implement the ASEAN mutual recognition agreement for BE study reports of generic medicinal products.

In its consultation document, the FDA clarifies that while it would accept the BE study reports from ASEAN-listed BE centers...

More from Generics

US FTC Continues Effort To Eliminate Orange Book’s Improper Patent Listings

 
• By Urtė Fultinavičiūtė

In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which led to missed guidance publication deadlines.

Aurobindo, MSN Fail To Beat US Nuplazid Patent Expiring In August 2038

 
• By Dean Rudge

Acadia’s Nuplazid for hallucinations and delusions associated with Parkinson’s disease psychosis appears safe from generic competition until well into the next decade, following a favorable infringement and validity decision by a US district court.

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 
• By Sarah Karlin-Smith

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.

More from Biosimilars & Generics